194 related articles for article (PubMed ID: 34615860)
1. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Clemens SAC; Folegatti PM; Emary KRW; Weckx LY; Ratcliff J; Bibi S; De Almeida Mendes AV; Milan EP; Pittella A; Schwarzbold AV; Sprinz E; Aley PK; Bonsall D; Fraser C; Fuskova M; Gilbert SC; Jenkin D; Kelly S; Kerridge S; Lambe T; Marchevsky NG; Mujadidi YF; Plested E; Ramasamy MN; Simmonds P; Golubchik T; Voysey M; Pollard AJ; ;
Nat Commun; 2021 Oct; 12(1):5861. PubMed ID: 34615860
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Emary KRW; Golubchik T; Aley PK; Ariani CV; Angus B; Bibi S; Blane B; Bonsall D; Cicconi P; Charlton S; Clutterbuck EA; Collins AM; Cox T; Darton TC; Dold C; Douglas AD; Duncan CJA; Ewer KJ; Flaxman AL; Faust SN; Ferreira DM; Feng S; Finn A; Folegatti PM; Fuskova M; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hallis B; Heath PT; Hay J; Hill HC; Jenkin D; Kerridge S; Lazarus R; Libri V; Lillie PJ; Ludden C; Marchevsky NG; Minassian AM; McGregor AC; Mujadidi YF; Phillips DJ; Plested E; Pollock KM; Robinson H; Smith A; Song R; Snape MD; Sutherland RK; Thomson EC; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Williams CJ; Hill AVS; Lambe T; Gilbert SC; Voysey M; Ramasamy MN; Pollard AJ; ; ;
Lancet; 2021 Apr; 397(10282):1351-1362. PubMed ID: 33798499
[TBL] [Abstract][Full Text] [Related]
3. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Voysey M; Costa Clemens SA; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Clutterbuck EA; Collins AM; Cutland CL; Darton TC; Dheda K; Dold C; Duncan CJA; Emary KRW; Ewer KJ; Flaxman A; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Galiza E; Goodman AL; Green CM; Green CA; Greenland M; Hill C; Hill HC; Hirsch I; Izu A; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Libri V; Lillie PJ; Marchevsky NG; Marshall RP; Mendes AVA; Milan EP; Minassian AM; McGregor A; Mujadidi YF; Nana A; Padayachee SD; Phillips DJ; Pittella A; Plested E; Pollock KM; Ramasamy MN; Ritchie AJ; Robinson H; Schwarzbold AV; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; White T; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Mar; 397(10277):881-891. PubMed ID: 33617777
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M; Clemens SAC; Madhi SA; Weckx LY; Folegatti PM; Aley PK; Angus B; Baillie VL; Barnabas SL; Bhorat QE; Bibi S; Briner C; Cicconi P; Collins AM; Colin-Jones R; Cutland CL; Darton TC; Dheda K; Duncan CJA; Emary KRW; Ewer KJ; Fairlie L; Faust SN; Feng S; Ferreira DM; Finn A; Goodman AL; Green CM; Green CA; Heath PT; Hill C; Hill H; Hirsch I; Hodgson SHC; Izu A; Jackson S; Jenkin D; Joe CCD; Kerridge S; Koen A; Kwatra G; Lazarus R; Lawrie AM; Lelliott A; Libri V; Lillie PJ; Mallory R; Mendes AVA; Milan EP; Minassian AM; McGregor A; Morrison H; Mujadidi YF; Nana A; O'Reilly PJ; Padayachee SD; Pittella A; Plested E; Pollock KM; Ramasamy MN; Rhead S; Schwarzbold AV; Singh N; Smith A; Song R; Snape MD; Sprinz E; Sutherland RK; Tarrant R; Thomson EC; Török ME; Toshner M; Turner DPJ; Vekemans J; Villafana TL; Watson MEE; Williams CJ; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2021 Jan; 397(10269):99-111. PubMed ID: 33306989
[TBL] [Abstract][Full Text] [Related]
5. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer KJ; Barrett JR; Belij-Rammerstorfer S; Sharpe H; Makinson R; Morter R; Flaxman A; Wright D; Bellamy D; Bittaye M; Dold C; Provine NM; Aboagye J; Fowler J; Silk SE; Alderson J; Aley PK; Angus B; Berrie E; Bibi S; Cicconi P; Clutterbuck EA; Chelysheva I; Folegatti PM; Fuskova M; Green CM; Jenkin D; Kerridge S; Lawrie A; Minassian AM; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Song R; Snape MD; Tarrant R; Voysey M; Watson MEE; Douglas AD; Hill AVS; Gilbert SC; Pollard AJ; Lambe T;
Nat Med; 2021 Feb; 27(2):270-278. PubMed ID: 33335323
[TBL] [Abstract][Full Text] [Related]
6. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
Katikireddi SV; Cerqueira-Silva T; Vasileiou E; Robertson C; Amele S; Pan J; Taylor B; Boaventura V; Werneck GL; Flores-Ortiz R; Agrawal U; Docherty AB; McCowan C; McMenamin J; Moore E; Ritchie LD; Rudan I; Shah SA; Shi T; Simpson CR; Barreto ML; Oliveira VA; Barral-Netto M; Sheikh A
Lancet; 2022 Jan; 399(10319):25-35. PubMed ID: 34942103
[TBL] [Abstract][Full Text] [Related]
7. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
Fischer RJ; van Doremalen N; Adney DR; Yinda CK; Port JR; Holbrook MG; Schulz JE; Williamson BN; Thomas T; Barbian K; Anzick SL; Ricklefs S; Smith BJ; Long D; Martens C; Saturday G; de Wit E; Gilbert SC; Lambe T; Munster VJ
Nat Commun; 2021 Oct; 12(1):5868. PubMed ID: 34620866
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
12. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Koen AL; Izu A; Baillie V; Kwatra G; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Bhikha S; Bhiman JN; du Plessis J; Esmail A; Horne E; Hwa SH; Oommen-Jose A; Lambe T; Laubscher M; Malahleha M; Benade G; McKenzie S; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Taoushanis C; Tegally H; Thombrayil A; Villafana TL; Gilbert S; Pollard AJ; Madhi SA
Vaccine; 2023 May; 41(23):3486-3492. PubMed ID: 37149443
[TBL] [Abstract][Full Text] [Related]
14. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Barrett JR; Belij-Rammerstorfer S; Dold C; Ewer KJ; Folegatti PM; Gilbride C; Halkerston R; Hill J; Jenkin D; Stockdale L; Verheul MK; Aley PK; Angus B; Bellamy D; Berrie E; Bibi S; Bittaye M; Carroll MW; Cavell B; Clutterbuck EA; Edwards N; Flaxman A; Fuskova M; Gorringe A; Hallis B; Kerridge S; Lawrie AM; Linder A; Liu X; Madhavan M; Makinson R; Mellors J; Minassian A; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Rollier CS; Song R; Snape MD; Tarrant R; Taylor S; Thomas KM; Voysey M; Watson MEE; Wright D; Douglas AD; Green CM; Hill AVS; Lambe T; Gilbert S; Pollard AJ;
Nat Med; 2021 Feb; 27(2):279-288. PubMed ID: 33335322
[TBL] [Abstract][Full Text] [Related]
15. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
[TBL] [Abstract][Full Text] [Related]
18. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
19. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
20. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
